Tova Waks

5.8k total citations · 2 hit papers
54 papers, 4.5k citations indexed

About

Tova Waks is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Tova Waks has authored 54 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 33 papers in Immunology and 17 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Tova Waks's work include CAR-T cell therapy research (33 papers), Monoclonal and Polyclonal Antibodies Research (17 papers) and Immune Cell Function and Interaction (15 papers). Tova Waks is often cited by papers focused on CAR-T cell therapy research (33 papers), Monoclonal and Polyclonal Antibodies Research (17 papers) and Immune Cell Function and Interaction (15 papers). Tova Waks collaborates with scholars based in Israel, United States and Germany. Tova Waks's co-authors include Zelig Eshhar, G. Gross, Daniel Schindler, Eran Elinav, Ehud Zigmond, Dan Blat, Zoya Alteber, Guy Gorochov, Cheryl Fitzer‐Attas and Alon Harmelin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Tova Waks

54 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.

1993 1.2k citations Zelig Eshhar, Tova Waks et al. profile →
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

1989 1.2k citations Tova Waks, Zelig Eshhar et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tova Waks Israel	26	3.7k	2.1k	1.2k	1.2k	1.0k	54	4.5k
Andreas Hombach Germany	42	4.5k 1.2×	2.5k 1.2×	1.4k 1.1×	1.4k 1.2×	1.3k 1.3×	104	5.4k
Carmine Carpenito United States	22	4.3k 1.2×	2.8k 1.3×	1.6k 1.3×	1.4k 1.2×	1.2k 1.2×	37	5.8k
G. Gross Israel	11	2.6k 0.7×	1.3k 0.6×	792 0.7×	836 0.7×	743 0.7×	15	2.9k
Daniel Sommermeyer United States	25	3.4k 0.9×	1.5k 0.7×	1.2k 1.0×	1.1k 0.9×	1.1k 1.1×	39	3.8k
Carolina Berger United States	28	3.0k 0.8×	1.5k 0.7×	1.2k 1.0×	1.1k 1.0×	782 0.8×	49	3.9k
Mohamad Hamieh United States	14	3.8k 1.0×	1.5k 0.7×	1.7k 1.4×	1.2k 1.0×	1.3k 1.3×	26	4.6k
Linda Rogers-Freezer United States	9	4.9k 1.3×	4.4k 2.0×	1.6k 1.3×	1.4k 1.2×	529 0.5×	10	6.4k
Daniel J. Powell United States	49	6.8k 1.8×	5.3k 2.5×	2.0k 1.6×	1.5k 1.3×	1.4k 1.4×	118	8.8k
Mathilde Poussin United States	24	2.1k 0.6×	1.1k 0.5×	679 0.6×	595 0.5×	767 0.8×	41	2.8k
Markus Chmielewski Germany	30	3.5k 0.9×	1.7k 0.8×	1.1k 0.9×	1.0k 0.9×	1.2k 1.2×	38	4.0k

Countries citing papers authored by Tova Waks

Since Specialization

Citations

This map shows the geographic impact of Tova Waks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tova Waks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tova Waks more than expected).

Fields of papers citing papers by Tova Waks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tova Waks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tova Waks. The network helps show where Tova Waks may publish in the future.

Co-authorship network of co-authors of Tova Waks

This figure shows the co-authorship network connecting the top 25 collaborators of Tova Waks. A scholar is included among the top collaborators of Tova Waks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tova Waks. Tova Waks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Horn, Galit, et al.. (2023). Nanoscale CAR Organization at the Immune Synapse Correlates with CAR-T Effector Functions. Cells. 12(18). 2261–2261. 4 indexed citations

2.

Horn, Galit, Tova Waks, Ido Laskov, et al.. (2022). Comparing Intraperitoneal and Intravenous Personalized ErbB2CAR-T for the Treatment of Epithelial Ovarian Cancer. Biomedicines. 10(9). 2216–2216. 9 indexed citations

3.

Aharon, Anat, et al.. (2021). Extracellular Vesicles Derived from Chimeric Antigen Receptor-T Cells: A Potential Therapy for Cancer. Human Gene Therapy. 32(19-20). 1224–1241. 46 indexed citations

4.

Rousso-Noori, Liat, Tova Waks, Anat Globerson Levin, et al.. (2021). P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas. Nature Communications. 12(1). 3615–3615. 31 indexed citations

5.

Blat, Dan, Ehud Zigmond, Zoya Alteber, Tova Waks, & Zelig Eshhar. (2014). Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen-Specific Regulatory T Cells. Molecular Therapy. 22(5). 1018–1028. 189 indexed citations

6.

Servais, Charlotte, Tova Waks, Markus Chmielewski, et al.. (2012). Redirected T Cells That Target Pancreatic Adenocarcinoma Antigens Eliminate Tumors and Metastases in Mice. Gastroenterology. 143(5). 1375–1384.e5. 86 indexed citations

7.

Artzy‐Schnirman, Arbel, R. Brener, Tova Waks, et al.. (2012). Mixed Alkanethiol Monolayers on Submicrometric Gold Patterns: A Controlled Platform for Studying Cell–Ligand Interactions. Nano Letters. 12(9). 4992–4996. 11 indexed citations

8.

Elinav, Eran, et al.. (2009). Amelioration of Colitis by Genetically Engineered Murine Regulatory T Cells Redirected by Antigen-Specific Chimeric Receptor. Gastroenterology. 136(5). 1721–1731. 143 indexed citations

9.

Kela, Itai, Alon Harmelin, Tova Waks, et al.. (2009). Interspecies comparison of prostate cancer gene‐expression profiles reveals genes associated with aggressive tumors. The Prostate. 69(10). 1034–1044. 11 indexed citations

10.

Agemy, Lilach, Alon Harmelin, Tova Waks, et al.. (2008). Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts. The Prostate. 68(5). 530–539. 15 indexed citations

11.

Elinav, Eran, Tova Waks, & Zelig Eshhar. (2008). Redirection of Regulatory T Cells With Predetermined Specificity for the Treatment of Experimental Colitis in Mice. Gastroenterology. 134(7). 2014–2024. 149 indexed citations

12.

Pinthus, Jehonathan H., Tova Waks, Keren Kaufman‐Francis, et al.. (2004). Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. Journal of Clinical Investigation. 114(12). 1774–1781. 50 indexed citations

13.

Pinthus, Jehonathan H., Tova Waks, Keren Kaufman‐Francis, et al.. (2004). Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. Journal of Clinical Investigation. 114(12). 1774–1781. 57 indexed citations

14.

Pinthus, Jehonathan H., Tova Waks, Keren Kaufman‐Francis, et al.. (2003). Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes.. PubMed. 63(10). 2470–6. 62 indexed citations

15.

Mabjeesh, Nicola J., Sharon Biton, Sharon Engel, et al.. (2002). Unusual Alternative Splicing within the Human Kallikrein Genes KLK2 and KLK3 Gives Rise to Novel Prostate-specific Proteins. Journal of Biological Chemistry. 277(20). 18084–18090. 50 indexed citations

16.

Fitzer‐Attas, Cheryl, Daniel Schindler, Tova Waks, & Zelig Eshhar. (1997). Direct T Cell Activation by Chimeric Single Chain Fv-Syk Promotes Syk-Cbl Association and Cbl Phosphorylation. Journal of Biological Chemistry. 272(13). 8551–8557. 29 indexed citations

17.

Eshhar, Zelig, Cheryl Fitzer‐Attas, G Grosse, et al.. (1996). The T-body approach: potential for cancer immunotherapy. Springer Seminars in Immunopathology. 18(2). 199–209. 73 indexed citations

18.

Waks, Tova, et al.. (1994). Functional expression in mast cells of chimeric receptors with antibody specificity. Cell Biophysics. 24-25(1-3). 229–236. 7 indexed citations

19.

Stancovski, Ilana, Daniel Schindler, Tova Waks, et al.. (1993). Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.. The Journal of Immunology. 151(11). 6577–6582. 169 indexed citations

20.

Eshhar, Zelig, Gideon Strassmann, Tova Waks, & Edna Mozes. (1979). In vitro and in vivo induction of effector T cells mediating DTH responses to a protein and a synthetic polypeptide antigen. Cellular Immunology. 47(2). 378–389. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact